Patient characteristics
Patient no. . | Age, y . | Sex . | Disease state at SCT . | CD34+ 106/Kg . | CD3+ 104/Kg . | KIR-L mismatch in GvH direction . | GvHD . | Relapse, yes/no (d*) . | Outcome (d*) . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 24 | F | AML/ref | 11.1 | 1.0 | Yes | 0 | No | Died, infection (31) |
| 2 | 24 | F | AML/rel1 | 5.65 | 1.03 | Yes | 0 | No | Died, TRM (210) |
| 3 | 19 | M | AML/rel1 | 17.6 | 6.07 | No | 0 | Yes (49) | Died, relapse (91) |
| 4 | 21 | F | AML/rel1 | 14.5 | 0.86 | No | 0 | Yes (97) | Died, relapse (124) |
| 5 | 35 | F | AML/rel1 | 7.7 | 4.39 | Yes | 0 | Yes (87) | Died, relapse (90) |
| 6 | 38 | M | AML/CR2 | 7.3 | 1.5 | Yes | 0 | Yes (93) | Died, relapse (98) |
| 7 | 23 | F | AML/ref | 7.88 | 8.94 | Yes | 0 | Yes (117) | Died, relapse (188) |
| 8 | 15 | M | AML/rel1 | 8.61 | 3.3 | Yes | 0 | Yes (185) | Died, relapse (331) |
| 9 | 20 | M | AML/rel2 | 18.81 | 4.65 | Yes | 0 | No | Died, TRM (130) |
| 10 | 25 | F | AML/CR2 | 8.04 | 4.07 | Yes | 0 | Yes (138) | Died, relapse (154) |
Patient no. . | Age, y . | Sex . | Disease state at SCT . | CD34+ 106/Kg . | CD3+ 104/Kg . | KIR-L mismatch in GvH direction . | GvHD . | Relapse, yes/no (d*) . | Outcome (d*) . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 24 | F | AML/ref | 11.1 | 1.0 | Yes | 0 | No | Died, infection (31) |
| 2 | 24 | F | AML/rel1 | 5.65 | 1.03 | Yes | 0 | No | Died, TRM (210) |
| 3 | 19 | M | AML/rel1 | 17.6 | 6.07 | No | 0 | Yes (49) | Died, relapse (91) |
| 4 | 21 | F | AML/rel1 | 14.5 | 0.86 | No | 0 | Yes (97) | Died, relapse (124) |
| 5 | 35 | F | AML/rel1 | 7.7 | 4.39 | Yes | 0 | Yes (87) | Died, relapse (90) |
| 6 | 38 | M | AML/CR2 | 7.3 | 1.5 | Yes | 0 | Yes (93) | Died, relapse (98) |
| 7 | 23 | F | AML/ref | 7.88 | 8.94 | Yes | 0 | Yes (117) | Died, relapse (188) |
| 8 | 15 | M | AML/rel1 | 8.61 | 3.3 | Yes | 0 | Yes (185) | Died, relapse (331) |
| 9 | 20 | M | AML/rel2 | 18.81 | 4.65 | Yes | 0 | No | Died, TRM (130) |
| 10 | 25 | F | AML/CR2 | 8.04 | 4.07 | Yes | 0 | Yes (138) | Died, relapse (154) |
GvHD indicates graft-versus-host disease; AML, acute myeloid leukemia; ref, refractory; TRM, toxicity related mortality; rel, relapse; CR, complete remission; F, female; and M, male.
Days after SCT